Rona Therapeutics , a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback